Harbour BioMed announced an update and advancement of its global strategic collaboration with AstraZeneca (AZN), originally established in March 2025. The collaboration aims to discover and develop next-generation biotherapeutics, including antibody-drug conjugates, ADCs, and T cell engagers, leveraging the knowledge of both companies. Under the terms of the agreement, AstraZeneca will continue to nominate discovery programs to Harbour BioMed each year over the next four years, reflecting the continued progress of the partnership, and will retain the option to license these programs for further development. Harbour BioMed will be eligible to receive option and option exercise fees, development and commercial milestone payments, plus tiered royalties on future net sales on such licensed programs. The economic terms are consistent with the financial framework established in March 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca plans $2B manufacturing investment in Maryland
- RFK told CDC to change website language on autism and vaccines, NYT reports
- Quantum Computing News: New Error Control Shift and New Site Plans Guide the Next Phase for Key Quantum Stocks
- IonQ Tells Congress Its Quantum Systems Are Moving Into Early Real-World Use
- AstraZeneca treatment of multiple myeloma granted orphan designation